Symbols / TNXP
TNXP Chart
About
Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 182.74M |
| Enterprise Value | -21.34M | Income | -99.22M | Sales | 10.30M |
| Book/sh | 22.73 | Cash/sh | 16.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 81 | IPO | — |
| P/E | 0.05 | Forward P/E | -1.66 | PEG | — |
| P/S | 17.74 | P/B | 0.63 | P/C | — |
| EV/EBITDA | 0.22 | EV/Sales | -2.07 | Quick Ratio | 9.29 |
| Current Ratio | 9.89 | Debt/Eq | 0.18 | LT Debt/Eq | — |
| EPS (ttm) | 279.15 | EPS next Y | -8.60 | EPS Growth | — |
| Revenue Growth | 16.60% | Earnings | 2026-03-17 | ROA | -35.94% |
| ROE | -64.99% | ROIC | — | Gross Margin | 34.31% |
| Oper. Margin | -10.05% | Profit Margin | 0.00% | Shs Outstand | 12.79M |
| Shs Float | 11.77M | Short Float | 18.25% | Short Ratio | 4.87 |
| Short Interest | — | 52W High | 69.97 | 52W Low | 6.76 |
| Beta | 1.87 | Avg Volume | 489.30K | Volume | 228.76K |
| Target Price | $66.33 | Recom | Strong_buy | Prev Close | $14.19 |
| Price | $14.29 | Change | 0.70% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$66.33
Mean price target
2. Current target
$14.29
Latest analyst target
3. DCF / Fair value
$-61.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.29
Low
$64.00
High
$70.00
Mean
$66.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-20 | reit | Noble Capital Markets | Outperform → Outperform | $70 |
| 2024-07-22 | main | Alliance Global Partners | Buy → Buy | $11 |
| 2024-02-28 | init | Dawson James | — → Buy | $3 |
| 2023-08-01 | main | Alliance Global Partners | Buy → Buy | $8 |
| 2023-06-02 | main | Alliance Global Partners | Buy → Buy | $18 |
| 2021-08-31 | main | Alliance Global Partners | Buy → Buy | $3 |
| 2021-08-11 | main | Alliance Global Partners | Buy → Buy | $2 |
| 2021-02-25 | main | Alliance Global Partners | Buy → Buy | $4 |
- After 15-year gap, new non-opioid fibromyalgia drug improves pain and sleep - Stock Titan Fri, 30 Jan 2026 08
- Tonix Eyes TNX‑102 SL Expansion, But We Need To See Tonmya Revenue First (NASDAQ:TNXP) - Seeking Alpha ue, 20 Jan 2026 08
- Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail ue, 24 Feb 2026 21
- Discipline and Rules-Based Execution in TNXP Response - Stock Traders Daily Fri, 20 Feb 2026 08
- Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat Mon, 22 Dec 2025 08
- Tonix Pharmaceuticals Stock (TNXP) Opinions on Recent Price Surge - Quiver Quantitative Wed, 13 Aug 2025 07
- Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data - Yahoo Finance Wed, 29 Oct 2025 07
- Is TNXP stock good for income investors - July 2025 Trends & Long-Term Growth Stock Strategies - mfd.ru Sun, 22 Feb 2026 14
- TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals - TechStock² Sun, 07 Dec 2025 08
- Tonix (Nasdaq: TNXP) licenses TNX-4900 for chronic neuropathic pain from Rutgers - Stock Titan ue, 16 Dec 2025 08
- $TNXP stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 24 Nov 2025 08
- Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP) - Seeking Alpha Mon, 24 Nov 2025 08
- Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - Stock Titan ue, 09 Dec 2025 08
- Tonix Pharmaceuticals Stock (TNXP) Opinions on Recent Price Surge and FDA Update | TNXP Stock News - Quiver Quantitative Mon, 18 Aug 2025 07
- $TNXP stock is up 14% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 701 | 9407 | — | Stock Award(Grant) at price 13.42 per share. | SAENGER BRADLEY | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 418 | 15061 | — | Purchase at price 36.03 per share. | TAYLOR CAROLYN E. | Director | — | 2025-08-21 00:00:00 | D |
| 2 | 250 | 9000 | — | Purchase at price 36.00 per share. | TRECO JAMES | Director | — | 2025-08-20 00:00:00 | D |
| 3 | 4000 | 86200 | — | Purchase at price 21.55 per share. | LEDERMAN SETH | Chief Executive Officer | — | 2025-05-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -18.92M | -114.09M | -110.84M | -92.26M |
| TotalUnusualItems | -52.81M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -52.81M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -130.04M | -116.66M | -110.22M | -92.29M |
| ReconciledDepreciation | 3.42M | 4.29M | 1.25M | 50.00K |
| ReconciledCostOfRevenue | 7.76M | 4.74M | 0.00 | |
| EBITDA | -71.73M | -114.09M | -110.84M | -92.26M |
| EBIT | -75.15M | -118.38M | -112.09M | -92.31M |
| NetInterestIncome | 1.87M | 25.00K | ||
| InterestIncome | 1.87M | 25.00K | ||
| NormalizedIncome | -77.23M | -116.66M | -110.22M | -92.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -130.04M | -116.66M | -110.22M | -92.29M |
| TotalExpenses | 85.24M | 126.15M | 112.09M | 92.31M |
| TotalOperatingIncomeAsReported | -136.70M | -118.38M | -112.09M | -92.31M |
| DilutedAverageShares | 736.34K | 7.92K | 1.79K | 775.00 |
| BasicAverageShares | 736.34K | 7.92K | 1.79K | 775.00 |
| DilutedEPS | -176.60 | -14.72K | -65.40K | -119.08K |
| BasicEPS | -176.60 | -14.72K | -65.40K | -119.08K |
| DilutedNIAvailtoComStockholders | -130.04M | -116.66M | -116.88M | -92.29M |
| NetIncomeCommonStockholders | -130.04M | -116.66M | -116.88M | -92.29M |
| OtherunderPreferredStockDividend | 0.00 | |||
| PreferredStockDividends | 6.66M | |||
| NetIncome | -130.04M | -116.66M | -110.22M | -92.29M |
| NetIncomeIncludingNoncontrollingInterests | -130.04M | -116.66M | -110.22M | -92.29M |
| NetIncomeContinuousOperations | -130.04M | -116.66M | -110.22M | -92.29M |
| PretaxIncome | -130.04M | -116.66M | -110.22M | -92.29M |
| OtherIncomeExpense | -54.89M | 1.72M | 1.87M | |
| OtherNonOperatingIncomeExpenses | -2.08M | 1.72M | 1.87M | |
| SpecialIncomeCharges | -58.96M | 0.00 | ||
| WriteOff | 58.96M | 0.00 | ||
| GainOnSaleOfSecurity | 6.15M | |||
| NetNonOperatingInterestIncomeExpense | 1.87M | 25.00K | ||
| InterestIncomeNonOperating | 1.87M | 25.00K | ||
| OperatingIncome | -75.15M | -118.38M | -112.09M | -92.31M |
| OperatingExpense | 77.48M | 121.41M | 112.09M | 92.31M |
| OtherOperatingExpenses | -2.59M | |||
| ResearchAndDevelopment | 39.97M | 86.66M | 81.88M | 68.84M |
| SellingGeneralAndAdministration | 40.10M | 34.75M | 30.21M | 23.47M |
| GeneralAndAdministrativeExpense | 34.75M | 30.21M | 23.47M | |
| OtherGandA | 34.75M | 30.21M | 23.47M | |
| GrossProfit | 2.33M | 3.03M | 0.00 | |
| CostOfRevenue | 7.76M | 4.74M | 0.00 | |
| TotalRevenue | 10.09M | 7.77M | 0.00 | 0.00 |
| OperatingRevenue | 10.09M | 7.77M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 4.39M | 18.32K | 3.82K | 775.00 |
| ShareIssued | 4.39M | 18.32K | 3.82K | 775.00 |
| TotalDebt | 8.12M | 9.81M | 760.00K | 956.00K |
| TangibleBookValue | 139.44M | 94.82M | 207.06M | 218.72M |
| InvestedCapital | 144.22M | 112.09M | 207.18M | 218.72M |
| WorkingCapital | 100.69M | 28.88M | 112.60M | 167.33M |
| NetTangibleAssets | 139.44M | 94.82M | 207.06M | 218.72M |
| CapitalLeaseObligations | 632.00K | 902.00K | 760.00K | 956.00K |
| CommonStockEquity | 139.56M | 105.53M | 207.18M | 218.72M |
| TotalCapitalization | 144.22M | 112.09M | 207.18M | 218.72M |
| TotalEquityGrossMinorityInterest | 139.56M | 105.53M | 207.18M | 218.72M |
| StockholdersEquity | 139.56M | 105.53M | 207.18M | 218.72M |
| GainsLossesNotAffectingRetainedEarnings | -255.00K | -232.00K | -167.00K | -92.00K |
| OtherEquityAdjustments | -255.00K | -232.00K | -167.00K | -92.00K |
| RetainedEarnings | -730.69M | -600.66M | -470.04M | -359.82M |
| AdditionalPaidInCapital | 870.50M | 706.41M | 677.38M | 578.61M |
| CapitalStock | 4.00K | 0.00 | 12.00K | 16.00K |
| CommonStock | 4.00K | 0.00 | 12.00K | 16.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 23.33M | 48.93M | 18.51M | 22.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.03M | 30.05M | 328.00K | 467.00K |
| DerivativeProductLiabilities | 0.00 | 22.86M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 5.03M | 7.19M | 328.00K | 467.00K |
| LongTermCapitalLeaseObligation | 358.00K | 632.00K | 328.00K | 467.00K |
| LongTermDebt | 4.67M | 6.56M | ||
| CurrentLiabilities | 18.31M | 18.88M | 18.18M | 21.72M |
| OtherCurrentLiabilities | 697.00K | 1.40M | 659.00K | 673.00K |
| CurrentDeferredLiabilities | 1.82M | 2.98M | 3.27M | 2.83M |
| CurrentDeferredRevenue | 1.82M | 2.98M | 3.27M | 2.83M |
| CurrentDebtAndCapitalLeaseObligation | 3.09M | 2.62M | 432.00K | 489.00K |
| CurrentCapitalLeaseObligation | 274.00K | 270.00K | 432.00K | 489.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.50M | 4.36M | 3.65M | 2.87M |
| PayablesAndAccruedExpenses | 8.20M | 7.53M | 10.17M | 14.85M |
| CurrentAccruedExpenses | 3.66M | 3.74M | 2.10M | 1.57M |
| Payables | 4.55M | 3.78M | 8.07M | 13.28M |
| AccountsPayable | 4.55M | 3.78M | 8.07M | 13.28M |
| TotalAssets | 162.89M | 154.46M | 225.69M | 240.90M |
| TotalNonCurrentAssets | 43.89M | 106.69M | 94.91M | 51.85M |
| OtherNonCurrentAssets | 951.00K | 1.13M | 264.00K | 379.00K |
| NonCurrentPrepaidAssets | 19.00K | |||
| GoodwillAndOtherIntangibleAssets | 120.00K | 10.71M | 120.00K | 120.00K |
| OtherIntangibleAssets | 120.00K | 9.74M | 120.00K | |
| Goodwill | 0.00 | 965.00K | 0.00 | |
| NetPPE | 42.82M | 94.85M | 94.53M | 51.47M |
| AccumulatedDepreciation | -4.10M | -5.36M | -1.65M | -400.00K |
| GrossPPE | 46.91M | 100.21M | 96.18M | 51.87M |
| Leases | 34.00K | 34.00K | 34.00K | 23.00K |
| ConstructionInProgress | 0.00 | 1.37M | 41.92M | |
| OtherProperties | 12.69M | 22.73M | 19.16M | 1.26M |
| MachineryFurnitureEquipment | 1.37M | 2.37M | 1.89M | 756.00K |
| BuildingsAndImprovements | 24.50M | 66.75M | 65.64M | 0.00 |
| LandAndImprovements | 8.32M | 8.34M | 8.09M | 7.91M |
| CurrentAssets | 119.00M | 47.77M | 130.78M | 189.05M |
| OtherCurrentAssets | 3.73M | 2.57M | 2.50M | 2.66M |
| PrepaidAssets | 1.66M | 1.27M | 1.48M | |
| Inventory | 8.41M | 14.15M | 0.00 | |
| InventoriesAdjustmentsAllowances | -21.00K | 0.00 | ||
| OtherInventories | 508.00K | |||
| FinishedGoods | 5.12M | 7.49M | 0.00 | |
| WorkInProcess | 213.00K | 2.54M | 0.00 | |
| RawMaterials | 3.07M | 3.61M | 0.00 | |
| Receivables | 8.08M | 6.10M | 8.04M | 7.73M |
| OtherReceivables | 4.22M | 4.59M | 8.04M | 7.73M |
| AccruedInterestReceivable | 180.00K | 1.51M | 0.00 | |
| AccountsReceivable | 3.68M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 98.78M | 24.95M | 120.23M | 178.66M |
| CashAndCashEquivalents | 98.78M | 24.95M | 120.23M | 178.66M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -61.05M | -109.90M | -146.20M | -110.86M |
| RepurchaseOfCapitalStock | 0.00 | -13.96M | -47.25M | 0.00 |
| RepaymentOfDebt | -2.35M | 0.00 | ||
| IssuanceOfDebt | 0.00 | 8.94M | 0.00 | |
| IssuanceOfCapitalStock | 140.19M | 18.94M | 135.05M | 212.39M |
| CapitalExpenditure | -120.00K | -7.89M | -48.15M | -35.31M |
| InterestPaidSupplementalData | 1.23M | 88.00K | ||
| EndCashPosition | 99.68M | 25.85M | 120.47M | 178.90M |
| BeginningCashPosition | 25.85M | 120.47M | 178.90M | 77.31M |
| EffectOfExchangeRateChanges | 4.00K | -65.00K | -74.00K | -31.00K |
| ChangesInCash | 73.83M | -94.56M | -58.36M | 101.62M |
| FinancingCashFlow | 134.87M | 36.52M | 87.84M | 212.49M |
| CashFlowFromContinuingFinancingActivities | 134.87M | 36.52M | 87.84M | 212.49M |
| NetOtherFinancingCharges | -3.00M | 22.57M | ||
| ProceedsFromStockOptionExercised | 27.00K | 29.00K | 40.00K | 98.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | -6.66M | 0.00 |
| PreferredStockPayments | 0.00 | 0.00 | -47.25M | 0.00 |
| PreferredStockIssuance | 0.00 | 40.59M | 0.00 | |
| NetCommonStockIssuance | 140.19M | 4.97M | 94.46M | 212.39M |
| CommonStockPayments | 0.00 | -13.96M | 0.00 | |
| CommonStockIssuance | 140.19M | 18.94M | 94.46M | 212.39M |
| NetIssuancePaymentsOfDebt | -2.35M | 8.94M | 0.00 | |
| NetLongTermDebtIssuance | -2.35M | 8.94M | 0.00 | |
| LongTermDebtPayments | -2.35M | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 8.94M | 0.00 | |
| InvestingCashFlow | -120.00K | -29.07M | -48.15M | -35.31M |
| CashFlowFromContinuingInvestingActivities | -120.00K | -29.07M | -48.15M | -35.31M |
| NetBusinessPurchaseAndSale | 0.00 | -22.17M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -22.17M | 0.00 | |
| NetPPEPurchaseAndSale | -120.00K | -6.90M | -48.15M | -35.31M |
| SaleOfPPE | 0.00 | 999.00K | 0.00 | |
| PurchaseOfPPE | -120.00K | -7.89M | -48.15M | -35.31M |
| OperatingCashFlow | -60.92M | -102.00M | -98.05M | -75.56M |
| CashFlowFromContinuingOperatingActivities | -60.92M | -102.00M | -98.05M | -75.56M |
| ChangeInWorkingCapital | 5.78M | -35.00K | -2.00K | 5.78M |
| ChangeInOtherWorkingCapital | 2.00K | -11.00K | ||
| ChangeInOtherCurrentLiabilities | -13.00K | 35.00K | 2.00K | |
| ChangeInPayablesAndAccruedExpense | 2.12M | -1.70M | 160.00K | 5.27M |
| ChangeInAccruedExpense | 1.19M | 1.79M | 1.21M | 1.75M |
| ChangeInPayable | 927.00K | -3.49M | -1.04M | 3.53M |
| ChangeInAccountPayable | 927.00K | -3.49M | -1.04M | 3.53M |
| ChangeInPrepaidAssets | 3.61M | 1.57M | -164.00K | 518.00K |
| ChangeInInventory | 3.74M | 61.00K | 0.00 | |
| ChangeInReceivables | -3.68M | 0.00 | ||
| ChangesInAccountReceivables | -3.68M | 0.00 | ||
| OtherNonCashItems | 840.00K | 903.00K | 3.00M | |
| StockBasedCompensation | 4.78M | 9.28M | 10.91M | 7.90M |
| AssetImpairmentCharge | 60.45M | 0.00 | ||
| DepreciationAmortizationDepletion | 3.42M | 4.29M | 1.25M | 50.00K |
| DepreciationAndAmortization | 3.42M | 4.29M | 1.25M | 50.00K |
| OperatingGainsLosses | -6.15M | 221.00K | ||
| GainLossOnInvestmentSecurities | -6.15M | 283.00K | ||
| GainLossOnSaleOfPPE | 0.00 | -62.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -130.04M | -116.66M | -110.22M | -92.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TNXP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|